HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma

Frontiers in Oncology

卷:11

Pier Giulio Conaldi¹  Gioacchin Iannolo¹  Rosaria Tinnirello²  Cinzia Maria Chinnici³  Claudia Carcione³  Ester Badami³ 

[1] Department of Research, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IRCCS ISMETT), Palermo, Italy;

[2] Neuroscience Unit, Consiglio Nazionale delle Ricerche (CNR), Institute of Biomedicine and Molecular Immunology, Palermo, Italy;

[3] Regenerative Medicine and Immunotherapy Area, Fondazione Ri.MED, Palermo, Italy;

关键词: HCC;    liver;    HCV;    miR34;    DAA;    EV;   

DOI  :  10.3389/fonc.2021.803278

来源: DOAJ

【 摘 要 】

Since its identification, HCV has been considered one of the main causes of hepatitis and liver cancer. Currently, the molecular mechanisms of HCC development induced by HCV infection have not been sufficiently clarified. The recent discovery of novel treatments that inhibit HCV replication gave rise to new questions concerning HCC mechanisms. In particular, the HCV eradication mediated by new direct-acting antiviral (DAAs) drugs does not exclude the possibility of de novo HCC development; this finding opened more questions on the interplay between liver cells and the virus. Different groups have investigated the pathways leading to cancer recurrence in patients treated with DAAs. For this reason, we tried to gain molecular insights into the changes induced by HCV infection in the target liver cells. In particular, we observed an increase in microRNA34a (miR34a) expression following HCV infection of HCC cell line Huh7.5. In addition, Huh7.5 treated with extracellular vesicles (EVs) from the previously HCV-infected Huh7.5 underwent apoptosis. Since miR34 expression was increased in Huh7.5 EVs, we hypothesized a paracrine mechanism of viral infection mediated by miR34a cargo of EVs. The balance between viral infection and cell transformation may raise some questions on the possible use of antiviral drugs in association with antineoplastic treatment.

【 授权许可】

Unknown